Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification

Ochirjav, Enkhee; Enkhbat, Bayarmaa; Baldandorj, Tuul; Choe, Gheeyoung

doi:10.4132/jptm.2019.07.15

Cited by 3 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with recent molecular reclassification studies, we showed a distinct prognostic segregation of glioma subtypes with the 2016 WHO classification as well as a prognostic significance of IDH mutation over histological tumour grade [26][27][28][29]47]. Interestingly, however, was the significant prognostic difference found in OS between WHO grade II and III IDH-mutant astrocytoma patients.…”

Section: Discussionsupporting

confidence: 91%

“…[26], Orhirjav et al . [27] and Brito et al . [28] also reported oligodendroglial tumours and WHO grade II/III astrocytomas as the main targets of reclassification, whereas the French nationwide POLA cohort (cohort of high‐grade glioma with an oligodendroglial component) [29] showed most frequent classification changes among astrocytomas and glioblastomas, but less common re‐classification of oligodendroglial tumours.…”

Section: Discussionmentioning

confidence: 99%

“…The majority of the remaining WHO 2007 anaplastic oligodendrogliomas were reclassified as either IDH-wildtype or IDH-mutant astrocytic gliomas/ glioblastomas according to WHO 2016, which of course bears major consequences on postsurgical therapy and prognosis [25]. Recent studies by Iuchi et al [26], Orhirjav et al [27] and Brito et al [28] also reported oligodendroglial tumours and WHO grade II/ III astrocytomas as the main targets of reclassification, whereas the French nationwide POLA cohort (cohort of high-grade glioma with an oligodendroglial component) [29] showed most frequent classification changes among astrocytomas and glioblastomas, but less common re-classification of oligodendroglial tumours. The differences between these studies are largely related to the distribution of glioma subgroups in the individual cohorts and variable stringency in the histological criteria used for oligodendroglioma classification [30].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics

Petersen

Boldt

Sørensen

et al. 2020

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

Aims We aimed to reclassify a population‐based cohort of 529 adult glioma patients to evaluate the prognostic impact of the 2016 World Health Organization (WHO) central nervous system tumour classification. Moreover, we evaluated the feasibility of gene panel next‐generation sequencing (NGS) in daily diagnostics of 225 prospective glioma patients. Methods The retrospective cohort was reclassified according to WHO 2016 criteria by immunohistochemistry for IDH‐R132H, fluorescence in situ hybridization for 1p/19q‐codeletion and gene panel NGS. All tumours of the prospective cohort were subjected to NGS analysis up‐front. Results The entire population‐based cohort was successfully reclassified according to WHO 2016 criteria. NGS results were obtained for 98% of the prospective patients. Survival analyses in the population‐based cohort confirmed three major prognostic subgroups, that is, isocitrate dehydrogenase (IDH)‐mutant and 1p/19q‐codeleted oligodendrogliomas, IDH‐mutant astrocytomas and IDH‐wildtype glioblastomas. The distinction between WHO grade II and III was prognostic in patients with IDH‐mutant astrocytoma. The survival of patients with IDH‐wildtype diffuse astrocytomas carrying TERT promoter mutation and/or EGFR amplification overlapped with the poor survival of IDH‐wildtype glioblastoma patients. Conclusions Gene panel NGS proved feasible in daily diagnostics. In addition, our study confirms the prognostic role of glioma classification according to WHO 2016 in a large population‐based cohort. Molecular features of glioblastoma in IDH‐wildtype diffuse glioma were linked to poor survival corresponding to IDH‐wildtype glioblastoma patients. The distinction between WHO grade II and III retained prognostic significance in patients with IDH‐mutant diffuse astrocytic gliomas.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics

Petersen

Boldt

Sørensen

et al. 2020

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

show abstract

“…Assessment of the glioma for IDH mutations was recommended as a required molecular testing for "integrated diagnosis" in the 2016 revised WHO classification of tumors of the central nervous system. In addition to histologic grade, the clinical outcome needs to be described within these IDH categories (9). Current diagnostic, prognostic, and predictive considerations also depend on IDH status (10).…”

Section: Discussionmentioning

confidence: 99%

Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma

Lin

Chen

2021

Ann Transl Med

View full text Add to dashboard Cite

Gliomas are one of the most common tumors of the central nervous system, which cause significant morbidity and mortality. Glioblastoma (GBM) is an aggressive and debilitating disease, which is the most common primary brain tumor in adults. Despite optimal surgical resection followed by radiotherapy and adjuvant chemotherapy, prognosis of patients with GBM remain poor. Tumor-treating fields (TTFields), as a novel treatment approach, is being explored through increased clinical application. Herein, we report the case of a 46-year-old man who was diagnosed as anaplastic astrocytoma [World Health Organization (WHO)Ⅲ grade], IDH1 R132 mutation, IDH2 R172 mutation, and a methylated MGMT promoter, without 1p36 and 19q13 heterozygosity loss. About 2.5 months after surgery, the patient presented with seizures, aphasia, and memory loss. Following the first-line treatment, TTFields was shown to be a valuable treatment option to control clinical symptom burden. The use of TTFields was shown to prolong progression-free survival and delay the pathological upgradation to glioblastoma. Notably, combined TTFields and chemotherapy might be beneficial in terms of risk reduction for pathological upgradation. To the our current knowledge, this is the first case report that attempts to offer possible strategies based on TTFields toward delaying pathological upgradation from anaplastic astrocytoma (WHO Ⅲ grade) to glioblastoma.

show abstract

“…For histopathological examination, 3-μm-thick sections were stained with H&E. Histological diagnosis and grading were done according to the WHO classification of central nervous system tumors. 15,16 based on cellularity, pleomorphism, number of mitoses per 10 high-power field (HPF), presence or absence of microvascular proliferation, and necrosis.…”

Section: Histopathological Examinationmentioning

confidence: 99%

Role of Wilms’ tumor 1 in diagnosis and grading of astrocytomas

John Emmanuel Raju S,

Nalini B,

Rajesh

et al. 2023

Asian J Med Sci

View full text Add to dashboard Cite

Background: Wilms’ tumor 1 (WT1) mutation has recently been detected in gliomas. Growing data indicate that WT1 mutation plays a causal role in gliomagenesis and is overexpressed in most glioblastomas. Emerging immunotherapy targeting WT1 has shown to be effective in resistant glioblastomas in clinical trials. WT1 expression and its potential utility in various grades of astrocytomas is still unclear and needs further elucidation. The evaluation of WT1 can be done by molecular or immunohistochemical methods. As immunohistochemistry is easier with wider routine use, immunoexpression of this biomarker was studied. Aims and Objectives: This study aimed to evaluate WT1 immunoexpression across different histological grades of astrocytomas and differentiate low-grade astrocytomas from reactive astrogliosis. Materials and Methods: This was an observational prospective study on 54 cases of astrocytomas. Results: In the present study a total of 54 cases have been diagnosed as astrocytomas. Grade IV was the most common (31%) followed by grade II (44%). WT1 score correlated with histological tumor grades (P<0.001) with a higher score in a higher grade. It was also observed that different tumor grades depicted two distinct expression patterns. WT1 score and pattern were valuable in differentiating high- and low-grade astrocytomas. Conclusion: This study supports the oncogenic role of WT1 in astrocytomas. WT1 was found to be valuable in distinguishing different grades of astrocytomas. The scoring and distinctive patterns of WT1 can aid in distinguishing high-grade and low-grade astrocytomas. However, one needs to be careful in pilocytic astrocytomas in which there is a mixed expression. WT1, therefore, appears to be an attractive immunohistochemistry (IHC) marker to be used concomitantly with other IHC markers in astrocytomas. In addition, the frequent expression of WT1 in astrocytomas supports its promising role in immunotherapy and its potential to guide patient selection for targeted immunotherapy.

show abstract

Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification

Cited by 3 publications

References 25 publications

Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics

Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics

Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma

Role of Wilms’ tumor 1 in diagnosis and grading of astrocytomas

Contact Info

Product

Resources

About